Back to top
more

ADMA Biologics (ADMA)

(Real Time Quote from BATS)

$13.72 USD

13.72
67,026

+0.14 (1.03%)

Updated Jul 25, 2024 09:51 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Adma Biologics (ADMA) Stock Moves -1.31%: What You Should Know

Adma Biologics (ADMA) concluded the recent trading session at $13.58, signifying a -1.31% move from its prior day's close.

What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?

On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors

Adma Biologics (ADMA) reachead $13.05 at the closing of the latest trading day, reflecting a -1.81% change compared to its last close.

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

Smart Beta ETF report for FYC

Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics

ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.

Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?

Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.

Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable

Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing

Adma Biologics (ADMA) reachead $11.64 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.

Implied Volatility Surging for ADMA Biologics (ADMA) Stock Options

Investors need to pay close attention to ADMA Biologics (ADMA) stock based on the movements in the options market lately.

Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know

Adma Biologics (ADMA) concluded the recent trading session at $10.84, signifying a -1.54% move from its prior day's close.

Adma Biologics (ADMA) Increases Despite Market Slip: Here's What You Need to Know

In the most recent trading session, Adma Biologics (ADMA) closed at $10.71, indicating a +0.85% shift from the previous trading day.

Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It?

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks.com featured highlights ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education

ADMA Biologics, Northern Technologies, PlayAGS, Merchants Bank and Strategic Education have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap May's Rally

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, NTIC, AGS, MBIN, STRA.

Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year?

Here is how Adma Biologics (ADMA) and ResMed (RMD) have performed compared to their sector so far this year.

Adma Biologics (ADMA) Surpasses Q1 Earnings and Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of 60% and 6.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

Adma Biologics (ADMA) reachead $6.74 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?